Introduction
Valve leaflet thickening and reduced leaflet motion of bioprosthetic aortic valves have been observed after TAVI and SAVR in asymptomatic patients without an associated increase in transaortic valve gradients by means of four-dimensional volume-rendered CT (4DCT) 1, 2 With reference to their CT appearance, these phenomena are referred to as hypo-attenuating leaflet thickening (HALT) and the more severe hypo-attenuation affecting motion (HAM), respectively. Observations suggested that HALT and HAM were two stages of the same phenomenon, with leaflet thickening affecting leaflet motion at a more advanced stage. Typical examples of HALT and HAM are shown in Figure 1 . Reduced leaflet motion may not be detected by transthoracic echocardiography (TTE), whereas transoesophageal echocardiography (TEE) reveals a hyperechogenic, homogeneous mass located on the aortic aspect of the affected leaflet(s), preventing normal leaflet excursion.
In an analysis of pooled data from the Portico IDE study and the RESOLVE and SAVORY registries, 1 HALT and HAM were observed among various TAVI and SAVR devices in patients with aortic valve (AV) gradients within the normal range. Therapeutic anticoagulation was associated with a reduced prevalence of HAM compared to other antithrombotic therapies or no therapy, suggesting a thrombotic mechanism. Moreover, valve function was fully restored after resolution of the phenomenon by warfarin, suggesting that reduced motion is a result rather than a cause of valve leaflet thrombosis. The pooled analysis 1 included 62 patients enrolled in the SAVORY registry at the time of the analysis. This new report includes 43 additional patients, additional imaging and longer follow-up, allowing analysis and description of the natural history of HALT and HAM.
Methods Patient cohort
This study is a prospective assessment of leaflet thickening and reduced leaflet motion by means of 4DCT and evaluation of imaging results by a core laboratory among patients enrolled within the SAVORY registry. The SAVORY registry (ClinicalTrials.gov: NCT02426307) includes 105 patients (age > _55 years) who underwent successful SAVR or TAVI at the Rigshospitalet University Hospital, Copenhagen, Denmark. Each group was randomly selected from the Eastern Denmark Heart Registry in order to represented patient demographic and antithrombotic regimes used at the institution. Patients who underwent TAVI-in-SAVR or TAVIin-TAVI procedures or with renal dysfunction (eGFR <25 mL/min) were excluded. Jude Medical, MN, USA)). Prior to initiation, the study received approval by the Ethical Committee (The Capital Region, Copenhagen, Denmark) and all enrolled patients provided written informed consent for the CT scans and the use of anonymous data for research in accordance with the review board approval (RH-2016-111, I-Suite# 04625).
Data collection and imaging interpretation
Per protocol, patients underwent a first 4DCT scan between 1 and 6 months after valve implantation, and a second scan within 3-6 months after the first scan. Valvular haemodynamics, stroke volume and ejection fraction were assessed by TTE at the time of both CT scans. Post-implant antithrombotic therapy was at the treating physician's discretion, but was unchanged between the first and second scans. Analysis of CT data was performed by a dedicated core laboratories at The Heart Center Rigshospitalet, Copenhagen, Denmark and at CedarsSinai Heart Institute, Los Angeles, CA, USA. Evaluators were blinded for baseline variables, antithrombotic medication, clinical events and outcome of previous CT scans. Evaluation was performed according to methods earlier described. 1 In brief, in axial 4DCT images, normal leaflets are only visible in diastole. In contrast, leaflets with reduced motion appear as wedge-shaped or semilunar opacities in both systole and diastole ( Figure  1 ). CT scans were considered interpretable for HALT if leaflet coaptation was clearly seen in a diastolic phase using a two-dimensional multi-planar reconstruction. HALT was determined to be either present or absent by a careful scrutiny of axial multiplanar reconstruction images throughout the aortic root from the base of the leaflets to the leaflet tips. In the presence of HALT, leaflet motion was systematically evaluated by 4DCT. Leaflet motion was assessed for each leaflet individually, using a volume-rendered en face cine projection looking directly above the valve in a multi-phase reconstruction. 1 HAM was defined as a leaflet excursion reduced by more than 50% in relation to the bioprosthetic frame radius. Data from the first CT scan from 62 patients of the SAVORY cohort was also included in an earlier report. 1 
Analysis
Progression and regression of the phenomenon were defined as the development or the disappearance, respectively, of HALT and/or HAM between the first and second scan. Stability was defined as the absence of progression and regression. Timing of the CT scans was modelled by binary variables, using a 3-month cut-off for the interval between valve implantation and the first scan (consistent with the standard duration of antithrombotic therapy traditionally prescribed after TAVI) and a 5-months cut-off for the interval between the scans (mid-point of the time window for the second scan). Antithrombotic therapy was categorized as oral anticoagulation-including vitamin-K antagonists (VKA) and non-VKA oral anticoagulants (NOAC)-referred to as (N)OAC) vs. no anticoagulation (antiplatelet therapy (APT) or no therapy). Change in the aortic valve gradients from the first to the second scan were determined and ANOVA analysis performed to test for significant differences in patients with progression, regression or a stable status.
To examine factors associated with the evolution of HALT and HAM, logistic regression modelling was performed, including demographic and baseline variables, valve type, antithrombotic medication during the study period and the timing of both CT scans. A univariable logistic regression model was fitted for each individual factor. In the logistic regression analysis the penalized maximum likelihood estimation (Firth estimator) 3, 4 was used if the likelihood maximization algorithm failed to converge due to complete or quasi-complete separation. Multivariable logistic regression models were developed separately for progression and regression, including age, gender, timing of CT scans, and antithrombotic medication, as well as covariates with an associated P-value <0.15 in the univariable model. As these analyses were of an exploratory nature, a P-value <0.10 in the multivariable model was considered to indicate statistical significance.
Only patients with two fully interpretable CT scans (i.e. for both HALT and HAM) and no cross-over between the medication categories were included in the logistic regression analysis.
Results

Patients and computed tomography imaging
A total of 105 patients were enrolled in the SAVORY cohort (mean age: 78.1 ± 8.0 years, 48.6% male). Demographic and baseline data of the entire cohort are provided in the Supplementary material online.
A first and a second scan were available from all 105 patients and 101 patients, respectively ( Figure 2 ). Reasons for not performing a second CT session included patient death from reasons not related to the implanted valve (n = 1), hospitalization for gastrointestinal bleeding (n = 1), suspected but unconfirmed endocarditis (n = 1), and study withdrawal for non-valve related reasons (n = 1). A total of 17 patients were excluded from the logistic regression analysis due to incompletely documented CT data (n = 3), imaging that was not fully interpretable (n = 11), and cross-over between medication categories (n = 3). Thus, 84 patients were included in the analysis population (including 61 TAVI and 23 SAVR), with a first and second CT scan performed at mean intervals of 140 ± 152 days and 298 ± 141 days after valve implantation, respectively. Twenty-four patients (28.6%) received oral anticoagulation therapy throughout the study; 12 patients NOAC and 12 patients VKA. For the latter group, INR levels were within therapeutic range (2.0-3.0) for more than 70% of the time for all patients except one. Of the remaining 60 patients (71.4%), 52 were consistently on APT therapy until the second CT scan, while 8 patients did not receive antithrombotic therapy during at least one phase of the followup period. Among patients receiving anti-platelet therapy, 75% of the TAVI patients and 14% of the SAVR patients were on dual therapy at first CT scan, changing to 20 and 11%, respectively, at second scan.
Hypo-attenuating leaflet thickening and hypo-attenuation affecting motion prevalence
Hypo-attenuating leaflet thickening was observed during the study period in 32 patients (38.1%), while HAM was also evident in 17 patients (20.2%). First CT scans showing HALT were obtained at a mean interval after valve implantation of 159 ± 177 days (range: 21-596 days). The incidence was similar in SAVR and TAVI patients (see Ssupplementary material online, Table S2 ). Throughout the study period, all patients were free from symptoms or clinical signs suggestive of impaired aortic valve function, regardless of the presence of HALT [mean gradient: 7.0 ± 3.2 and 7.3 ± 3.4 mmHg for patients with and without HALT, respectively, at first scan (P = 0.75), and 7.1 ± 4.5 and 6.3 ± 3.1 mmHg at second scan (P = 0.77)] or HAM [mean gradient: 7.2 ± 2.4 and 7.1 ± 3.6 mmHg for patients with and without HAM, respectively, at first scan (P = 0.94), and 5.7 ± 3.3 mmHg and 6.4 ± 3.3 mmHg at second scan (P = 0.44)].
Overall hypo-attenuating leaflet thickening/hypo-attenuation affecting motion evolution Table 1 and Figure 3 shows the overall evolution pattern of the phenomenon between the first and second CT scan (see Supplementary material online, Table S2 ). Progression was observed in 13 of 84 patients (15.5%). Seven patients progressed towards HALT, while progression to HAM was observed in six patients. Second CT scans showing progression in these 13 patients were obtained at a mean interval of 323 days after valve implantation (range: 160-510 days).
Regression between the first and second scan was observed in nine patients (10.7%), including regression from HAM to HALT in two patients and regression to normal valve leaflets in seven patients.
For the remaining 62 patients (73.8%) the first and second CT scan showed the same status regarding HALT and HAM. Ten of these patients had HALT at both scans, including seven who also persistently showed HAM. The remaining 52 patients (61.9% of the analysis cohort) had normal valve leaflets at both scans. The mean interval between first and second CT scan was similar for the patients with stable status compared to those with either progression or regression (160 ± 45 days vs. 151 ± 47 days, respectively, P = 0.49).
Echocardiographic valve assessment
Of the 84 patients included in the analysis cohort, data on valve gradients at both CT scans were available from 74 patients. The mean changes in valve gradients were not clinically significant ( Table 2) . Moreover, differences between patients with progression, regression or stable status were not statistically significant. Throughout the study, none of the patients with HALT or HAM showed central aortic regurgitation.
Logistic regression modelling
Results from logistic regression modelling for progression of HALT and HAM are shown in Table 3 . Only baseline variables associated with a P-value <0.15 in the univariable model are shown. Complete univariable logistic regression model data from all variables is included in the Supplementary material online.
As the univariable model did not show a significant effect of the valve type (TAVI vs. SAVR) this variable was not included in the multivariable model. The multivariable model did not find an association between HALT/HAM progression and the timing of both CT scans. Anticoagulation (VKA or NOAC) had a significant and strong preventive effect against progression (OR: 0.014, [95% confidence interval (CI): 0.0003, 0.76], P = 0.036). None of the patients who experienced progression were on (N)OAC, while 33.8% of the patients without progression (i.e. showing regression or stability) were on (N)OAC. The univariable model showed a significant negative association between atrial fibrillation (AF) and progression, which was nonsignificant in the multivariable model.
Results from logistic regression modelling for the regression of HALT and HAM are shown in Table 4 . A first CT scan obtained at >3 months after valve implantation was associated with a nearly 14-fold higher odds of observing regression (OR: 13.97, P = 0.032), but no association was found with the timing of the second scan. Patients who experienced regression did not have significantly higher odds of being on (N)OAC.
Adverse clinical events
In the entire registry cohort (105 patients) one patient died and two patients had neurologic events. The patient who died 5 months after TAVI had an inconclusive first CT scan seven weeks before death. One patient had a TIA at 6 months post-TAVI and another patient had a TIA at 2 weeks and a stroke at 4 months after TAVI. Both patients with neurologic events had CT scans before and after the events that were positive for HAM. These two patients were part of the original cohort described earlier. 1 No patient developed syncope, heart failure or other signs of dysfunction of the aortic bioprosthesis. The model accounted for timing of the CT scans by means of binary variables (> 3 months after implantation and >5 months after first scan). The model accounted for timing of the CT scans by means of binary variables (>3 months after implantation and >5 months after first scan). 
Discussion
Our analysis suggests that HALT is a common finding after TAVI and SAVR, identified in 38% of the patients during the study. Moreover, reduced leaflet motion (HAM) was identified in approximately 50% of HALT cases. Regarding the temporal dynamics of HALT and HAM, three main aspects emerge from our observations: (i) development of the phenomenon may start at an early or late period after valve implantation; (ii) all possible patterns of evolution of HALT were noted, including variable progression, stability, and regression at different time intervals; (iii) once developed, the phenomenon may persist during a relatively long period, and then may or may not regress.
Accounting for all observed patterns of progression and regression, the phenomenon seems to evolve over several progressive and regressive stages, including development of HALT, often followed by reduced leaflet motion, with variable regression in reversed order towards normal valve leaflets.
The likelihood of observing progression was not influenced by the timing of the first CT scan (at <3 months vs. >3 months after implantation). This suggests that the period during which the phenomenon may start to develop is not restricted to a brief window after valve implantation, but may develop over a prolonged period. However, our results do not exclude the early development and the earliest scan showing HALT was obtained 21 days after valve implantation. This is consistent with observations reported by Pache et al., 2 who observed HALT in 10% of the patients at a median interval of 5 days after TAVI. Regression was more likely to be observed if the first CT scan was obtained at >3 months after implantation. First CT scans obtained later were more likely to capture the phenomenon in an advanced stage, and show regression in combination with the second scan. Based on this observation, it may be speculated that the phenomenon may take more than 3 months to reach its most advanced stage. Finally, the interval between the scans was not associated with the likelihood of regression. Seven of the nine patients with regression had completely normal valve leaflets in their second CT scan. It cannot be excluded that regression occurred in a relatively short time frame after the observation of HALT or HAM on the first CT scan, but was noticed substantially later due to the timing of the second CT scan. Therefore, these results do not unambiguously reveal the time required for regression to occur.
In the univariable model, AF was associated with a reduction in progression. This may be related to the use of oral anticoagulants in 22 of the 24 patients with AF. In contrast, the multivariable model identified AF as a non-significant predisposing factor for progression. With regard to this, it is noted that AF was also identified as an independent risk factor for thrombus formation on septal closure devices 5 under variable antithrombotic regimes. This may be due to the systemic prothrombotic state of AF patients 6 predisposing them to thrombus formation regardless of the underlying device substrate. Our results do not suggest a significant effect of the valve type (TAVI vs. SAVR) on the likelihood of progression or regression of HALT and HAM. Statistical modelling suggested that patients on oral anticoagulation were less likely to show progression than those on APT or no antithrombotic therapy. Of the 32 patients showing HALT during the study, only five were taking (N)OAC, none of whom demonstrated progression between scans. Although by multivariable analysis regression tended to be more likely in patients receiving oral anticoagulation compared with those on APT or no therapy, this difference did not reach statistical significance. Notably, six of nine patients showing regression were on APT therapy. It is possible that HALT may exhibit spontaneous regression as part of its natural history, regardless of pharmacotherapy.
The present study extends the results from recent reports examining the possible relationship between thrombosis in an advanced stage over aortic valve deterioration. Among 1521 TAVI patients, 7 valve haemodynamic deterioration (VHD), defined as a > _10 mmHg increase in the transprosthetic mean gradient compared with discharge, occurred in 4.5% of all patients, with absence of VKA at discharge remained an independent predictor of VHD (adjusted hazard ratio: 4.58, P = 0.04). In our study, leaflet thickening was not associated with marked increase in valve gradients. At a median duration of 253 days after valve implantation, we did not notice VHD, despite the presence of HALT and HAM. Nevertheless, the possibility that untreated subclinical leaflet thickening may evolve into valve thrombosis affecting haemodynamics with longer follow-up cannot be excluded. Recently, Hansson et al. 8 reported valve thrombosis in 28 of 405 patients (7%) at 1-3 months after TAVI of which five developed clinical obstructive valve thrombosis. With regard to the role of anticoagulants, the GALILEO study (NCT02556203), comparing rivaroxaban and antiplatelet agents after TAVI is of specific interest. Particularly, a sub-study (NCT02833948) of this trial in which imaging 4DCT at 3 months after valve implantation is performed may provide additional insights with regard to this phenomenon.
The present study is exploratory in nature and was not designed or powered to assess the correlation between HALT/HAM and clinical outcomes such as death and neurologic events. As such, the results need to be validated. Nevertheless, the finding of HALT and HAM in both scans of the two patients who had neurologic events warrants further investigation regarding the role of the phenomenon in potentially cardioembolic events. In this regard, while the majority of ischaemic strokes after TAVI or SAVR occur relatively soon after the procedure, 9 strokes also may occur at longer durations after valve implantation. Several additional limitations of this study should be noted. The use of two CT scans allowed examination of whether regression or progression of HALT/HAM occurred, but not the exact time of the occurrence. The variable interval after valve implantation at which CT imaging was performed may also be perceived as a limitation. However, this enabled us to sample the frequency and stability of this phenomenon at various points in time. The time course of leaflet thickening and specific patterns of progression and regression can only be speculative given the small number of patients studied and the availability of only two CT scans over a relative short time period. Ideally, a phenomenon developing through multiple stages over time should be assessed more frequently than in our study, although there are clearly concerns in repeated CT scanning regarding exposure to radiation and contrast. A further limitation is the exclusion of some patients from the statistical modelling for several reasons, which may have influenced the outcome of the analysis. The small number of patients and sparse data may have resulted in instability in estimating the parameters of some logistic models so that the odds ratios appeared at the extreme in some cases. Although multivariable modelling carries the risk of overfitting, the obtained estimates from the model did not indicate potential overfitting and the area under the ROC curve from the model indicated good discrimination.
Our observations may provide directions for future research on a variety of topics. First, whether VKA and NOAC therapy differ in efficacy for the prevention of HALT and HAM should be studied. Second, our results suggest that the occurrence of HALT and HAM is not restricted to a relatively brief post-implant interval but may persist over a long period after implantation. In view of this, different durations of OAC to prevent HALT and HAM should be studied to determine the optimal risk-benefit balance after aortic valve implantation, an understanding which also requires establishing how often these valve abnormalities translate into adverse clinical events. Finally, since the numbers for each valve iteration are too small to allow any conclusion on the relation between valve type and (ab)normal findings, larger studies are required to determine whether the rate of HALT and HAM differ after TAVI and SAVR as well as between different valve designs.
In conclusion, the originality of this study is the sequential evaluation of the phenomenon using repeated CTs showing how complex the phenomenon is with a potential for progression or regression. Thus, the study identified HALT and HAM as common findings after TAVI and SAVR, which may develop and regress at variable, and often prolonged intervals after implantation. Results suggest a possible protective effect of oral anticoagulation, and do not exclude occasional regression without anticoagulation. However, the findings here are only hypothesis generating and need confirmation. Finally, we have much to learn for a better understanding, and thereafter management, of this phenomenon.
